Clinical Validation of Human Papilloma Virus Circulating Tumor DNA for Early Detection of Residual Disease After Chemoradiation in Cervical Cancer
Journal of Clinical Oncology · 01.02.2024 · 42 (4) · 431-440
DOI: 10.1200/jco.23.00954 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.02.2024. Verfasst von Kathy Han und 20 weiteren Autor:innen. Beteiligte Einrichtung: Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Uterine Cervical Neoplasms, Papillomavirus Infections. Die Arbeit wurde bisher 85-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE Most cervical cancers are caused by human papilloma virus (HPV), and HPV circulating tumor DNA (ctDNA) may identify patients at highest risk of relapse. Our pilot study using digital polymerase chain reaction (dPCR) showed that detectable HPV ctDNA at the end of chemoradiation (CRT) is associated with inferior progression-free survival (PFS) and that a next-generation sequencing approach (HPV-seq) may outperform dPCR. We aimed to prospectively validate HPV ctDNA as a tool for early detection of residual disease. METHODS This prospective, multicenter validation study accrued patients with stage IB-IVA cervical cancer treated with CRT between 2017 and 2022. Participants underwent phlebotomy at baseline, end of CRT, 4-6 weeks post-CRT, and 3 months post-CRT for HPV ctDNA levels. Plasma HPV genotype–specific DNA levels were quantified using both dPCR and HPV-seq. The primary end point was 2-year PFS. RESULTS With a median follow-up of 2.2 (range, 0.5-5.5) years, there were 24 PFS events among the 70 patients with HPV+ cervical cancer. Patients with detectable HPV ctDNA on dPCR at the end of CRT, 4-6 weeks post-CRT, and 3 months post-CRT had significantly worse 2-year PFS compared with those with undetectable HPV ctDNA (77% v 51%, P = .03; 82% v 15%, P < .001; and 82% v 24%, P < .001, respectively); the median lead time to recurrence was 5.9 months. HPV-seq showed similar results as dPCR. On multivariable analyses, detectable HPV ctDNA on dPCR and HPV-seq remained independently associated with inferior PFS. CONCLUSION Persistent HPV ctDNA after CRT is independently associated with inferior PFS. HPV ctDNA testing can identify, as early as at the end of CRT, patients at high risk of recurrence for future treatment intensification trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
- Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada.
- Department of Biostatistics, University Health Network, Toronto, Ontario, Canada.
- Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
- Department of Obstetrics and Gynecology, University of Toronto, Toronto, Canada.
- Jewish General Hospital, Montreal, Quebec, Canada.
ORCID-Profile: Kathy Han, Zeynep Baskurt, Elizabeth Barnes, Jennifer Croke, Sarah E Ferguson, Anthony Fyles, Lilian Gien, Stephanie Lheureux, Ur Metser, Michael Milosevic, Scott V Bratman
Zitieren
APA
Han, K., Zou, J., Zhao, Z., Baskurt, Z., Zheng, Y., Barnes, E., Croke, J., Ferguson, S. E., Fyles, A., Gien, L., Gladwish, A., Lecavalier-Barsoum, M., Lheureux, S., Lukovic, J., Mackay, H., Marchand, E. L., Metser, U., Milosevic, M., Taggar, A. S., …, & Leung, E. (2024). Clinical Validation of Human Papilloma Virus Circulating Tumor DNA for Early Detection of Residual Disease After Chemoradiation in Cervical Cancer. Journal of Clinical Oncology, 42(4), 431-440. https://doi.org/10.1200/jco.23.00954
Vancouver
Han K, Zou J, Zhao Z, Baskurt Z, Zheng Y, Barnes E, et al. Clinical Validation of Human Papilloma Virus Circulating Tumor DNA for Early Detection of Residual Disease After Chemoradiation in Cervical Cancer. Journal of Clinical Oncology. 2024;42(4):431-440. doi:10.1200/jco.23.00954
BibTeX
@article{Han2024,
author = {Han, Kathy and Zou, Jinfeng and Zhao, Zhen and Baskurt, Zeynep and Zheng, Yangqiao and Barnes, Elizabeth and Croke, Jennifer and Ferguson, Sarah E and Fyles, Anthony and Gien, Lilian and Gladwish, Adam and Lecavalier-Barsoum, Magali and Lheureux, Stephanie and Lukovic, Jelena and Mackay, Helen and Marchand, Eve-Lyne and Metser, Ur and Milosevic, Michael and Taggar, Amandeep S and Bratman, Scott V and Leung, Eric},
title = {Clinical Validation of Human Papilloma Virus Circulating Tumor DNA for Early Detection of Residual Disease After Chemoradiation in Cervical Cancer},
journal = {Journal of Clinical Oncology},
year = {2024},
volume = {42},
number = {4},
pages = {431--440},
doi = {10.1200/jco.23.00954}
}
EUVIMED